Skip to main content
. Author manuscript; available in PMC: 2023 Mar 1.
Published in final edited form as: J Immunol. 2022 Aug 5;209(5):864–873. doi: 10.4049/jimmunol.2200145

Figure 3. DCs and activated TCD4+ are unable to present epitope derived from AT2-inactivated and K574D fusion-deficient HIV-1.

Figure 3.

DCs and activated TCD4+ were cultured and infected with WT HIV-1 as described in Materials and Methods. AT2-treated HIV-1 and K574D fusion-deficient HIV-1 were added to DCs and activated TCD4+ 12 hours prior to the beginning of the assay. (A) DCs and (B) TCD4+ were assessed for their ability to present AT2-treated HIV-1 after 8 hours of coculture with HIV-1-specific TCD4+. IL-2, TNFα, and IFNγ expression was assessed by flow cytometry. (C) DCs and (D) activated TCD4+ were assessed for their ability to present fusion-deficient HIV-1 in a similar manner. Fold induction of each cytokine is shown, using DMSO as a baseline. Each dot represents an independent experiment. Bars represent mean ± SD. One way ANOVA, *p<0.05, **p<0.01, ****p<0.001.